Notice2026-19589
Foreign-Trade Zone (FTZ) 40, Notification of Proposed Production Activity; Olon USA LLC; (Active Pharmaceutical Ingredients); Concord, Ohio
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 24, 2026
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 184 (Thursday, September 24, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 184 (Thursday, September 24, 2026)]
[Notices]
[Pages 60581-60582]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-19589]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-118-2026]
Foreign-Trade Zone (FTZ) 40, Notification of Proposed Production
Activity; Olon USA LLC; (Active Pharmaceutical Ingredients); Concord,
Ohio
The Cleveland Cuyahoga County Port Authority, grantee of FTZ 40,
submitted a notification of proposed production activity to the FTZ
Board (the Board) on behalf of Olon USA LLC (Olon) for Olon's facility
in Concord, Ohio within FTZ 40. The notification conforming to the
requirements of the Board's regulations (15 CFR 400.22) was received on
September 15, 2026.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
The proposed finished products include: API ``D'' Cancer Treatment
Drug Product; API ``R1'' Breast Cancer
[[Page 60582]]
Treatment Product; API ``I'' Kidney Disorder Treatment Product; API
``R2'' Chronic Urticaria Treatment Product; and API ``A'' Ph+CML Cancer
Treatment Product with duty rate ranges from 3.7 to 6.5%.
The proposed foreign-status materials/components include: Kinase
Inhibitor; Enzyme B-Raf Inhibitor; Oral Complement Inhibitor; Oral
Bruton's Tyrosine Kinase Inhibitor; Protein Kinase Inhibitor; Succinic
Acid; Methanesulfonic Acid; Plastic Bags; and Foil Bags with duty rate
ranges from 3% to 6.5%.
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#791f0d03390d0b181d1c571e160f"><span class="__cf_email__" data-cfemail="accad8d6ecd8decdc8c982cbc3da">[email protected]</span></a>. The closing period for their receipt is November 3,
2026.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact John Frye at <a href="/cdn-cgi/l/email-protection#e7ad888f89c9a1959e82a79395868382c9808891"><span class="__cf_email__" data-cfemail="dd97b2b5b3f39bafa4b89da9afbcb9b8f3bab2ab">[email protected]</span></a>.
Dated: September 21, 2026.
Colin Agostisi,
Executive Secretary.
[FR Doc. 2026-19589 Filed 9-23-26; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 24, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.